Induced proximity biology – bringing two molecules together to cause some kind of reaction – is in its heyday via the field of targeted protein degradation with proteolysis targeting chimera (PROTAC) therapeutics reaching previously undruggable targets. Now, Halda Therapeutics, with $126m in new venture capital financing, will conduct its first clinical trial of a novel induced proximity modality from a PROTAC pioneer.
Key Takeaways
-
Halda Therapeutics raised $126m to take its first RIPTAC, invented at the company and inspired by the research of PROTAC pioneer Craig Crews at Yale, into the clinic in 2025 in prostate cancer.
Halda founder and Yale University professor Craig Crews, founder of PROTAC developer Arvinas, Inc., wanted to inspire the...